US FDA gives priority to Hutchmed's colorectal cancer treatment
26th May 2023 13:13
(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.
Read moreHutchmed's gastric cancer treatment accepted for review in China
18th Apr 2023 12:30
(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.
Read moreHutchmed completes rolling FDA submission for colorectal cancer drug
31st Mar 2023 13:47
(Sharecast News) - Pharmaceuticals developer Hutchmed China announced the completion of its rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor 'fruquintinib'.
Read moreHutchmed enrols last patient in lymphoma treatment trial
27th Feb 2023 11:39
(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the treatment of relapsed or refractory follicular lymphoma (FL), which is a subtype of non-Hodgkin's lymphoma.
Read moreHutchmed China completes enrolment for solveplenib clinical trial
3rd Jan 2023 13:47
(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.
Read moreHutchmed refocuses strategy away from early-stage studies
15th Nov 2022 11:30
(Sharecast News) - Hutchmed China updated the market on its strategy on Tuesday, following an "in-depth evaluation" of the business.
Read moreHutchmed reports positive results from recent fruquintinib study
14th Nov 2022 09:40
(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma on Monday.
Read moreHutchmed upbeat on latest study results for colorectal cancer treatment
8th Aug 2022 12:42
(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib' met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer (CRC).
Read moreHutchmed China confident after being added to SEC list
31st Mar 2022 10:04
(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.
Read moreHutchmed China losses widen as it appoints new CEO
3rd Mar 2022 12:54
(Sharecast News) - Hutchmed China reported a 56% increase in total revenues in its full-year results on Thursday, to $356.1m (£266.17m), although its losses widened, as it announced the departure of its chief executive officer and the appointment of his replacement.
Read moreTwo Hutchmed drugs included in China's 2022 reimbursement list
3rd Dec 2021 13:23
(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.
Read moreHutchmed strikes collaboration deal with Epizyme
9th Aug 2021 12:35
(Sharecast News) - Commercial-stage biotechnology company Hutchmed China announced a collaboration to research, develop, manufacture and commercialise 'Tazverik' in Greater China on Monday, including mainland China, Hong Kong, Macau and Taiwan.
Read moreHutchmed makes first commercial sale of 'Orpathys' in China
13th Jul 2021 15:42
(Sharecast News) - Hutchmed China announced the first commercial sale in China of 'Orpathys', or savolitinib, on Tuesday, which is its "oral, potent, and highly-selective" small molecule inhibitor of MET, a receptor tyrosine kinase.
Read moreHutchmed China launches Hong Kong public offering
18th Jun 2021 08:52
(Sharecast News) - Hutchmed China announced the launch of its Hong Kong public offering on Friday, as part of its global offering of 104 million new shares, proposing the primary listing of its ordinary shares on the main board of the Hong Kong Stock Exchange under the stock code '13'.
Read moreHutchison Chi-Med begins latest trial of fruquintinib
4th Sep 2020 14:13
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.
Read more